Beyond their ability to lower HbA1c levels and improve metabolic control in T2DM, SGLT2 inhibitors also reduce pulmonary artery pressure in diabetic patients with heart failure, decreasing the incidence of major adverse cardiovascular events [9]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.